Summary
- Supreme Court stays government order omitting Rule 170 for Ayurveda, Siddha, and Unani drug ads
- Centre’s decision went against court orders to curb misleading health and medicinal product advertisements
- Rule 170 required licensing permission for drug manufacturers before publishing ads related to disease claims
- Court directs Centre to clarify position on clinical trials for approving Ayush drugs
